Canada's Psilocybin Patients: Compassionate Access & Real-World Outcomes
An overview of how Canadian patients have accessed psilocybin through Health Canada's Special Access Program — covering eligibility, the clinical framework, patient-reported outcomes, and what real-world use reveals about psilocybin's therapeutic promise beyond controlled trial settings.
Content Coming Soon
This resource is being prepared and will be available shortly.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar.
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. (2023). Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. International Journal of Mental Health Nursing, 32(4), 1025–1037. https://doi.org/10.1111/inm.13127
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
Shop Related Spores
Laboratory-grade Psilocybe cubensis spore syringes for microscopy research.